Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GKB OphthalmicsNSE:GKB 44 EV-to-EBITDA is 3.70 as of Aug. 25, 2026, which is 69% below its 10-year median of 12.06. GuruFocus rates NSE:GKB with a GF Score™ of 44/100 and a GF Value™ of ₹126.23 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 516 Medical Devices & Instruments companies, GKB Ophthalmics ranks better than 89.73% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, GKB Ophthalmics's enterprise value is ₹420 Mil.
GKB Ophthalmics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹114 Mil. Therefore, GKB Ophthalmics's EV-to-EBITDA for today is 3.70.
The historical rank and industry rank for GKB Ophthalmics's EV-to-EBITDA or its related term are showing as below:
NSE:GKB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -35.32 Med: 12.06 Max: 93
Current: 3.89
During the past 13 years, the highest EV-to-EBITDA of GKB Ophthalmics was 93.00. The lowest was -35.32. And the median was 12.06.
NSE:GKB's EV-to-EBITDA is ranked better than 89.73% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs NSE:GKB: 3.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GKB Ophthalmics's PE Ratio (TTM) for today is calculated as:
GKB Ophthalmics's share price for today is ₹63.00.
GKB Ophthalmics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.380.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for GKB Ophthalmics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GKB vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, GKB Ophthalmics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GKB Ophthalmics EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, GKB Ophthalmics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where GKB Ophthalmics's EV-to-EBITDA falls into.
GKB Ophthalmics's current Enterprise Value is ₹420 Mil.
GKB Ophthalmics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹114 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKB Ophthalmics (NSE:GKB) has a EV-to-EBITDA of 3.70 as of Aug. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GKB Ophthalmics. This is 69% below median its historical median of 12.06. According to the industry distribution chart, GKB Ophthalmics ranks #53 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 10.3%.
Is GKB Ophthalmics' EV-to-EBITDA too high?
GKB Ophthalmics' current EV-to-EBITDA of 3.70 is 69% below median its 10-year median of 12.06. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.67. GKB Ophthalmics' value of 3.70 is 74.8% below this industry median. Based on the distribution chart, GKB Ophthalmics ranks #53 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, GKB Ophthalmics has a GF Score™ of 44/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GKB Ophthalmics' EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, GKB Ophthalmics ranks #53 out of 516 companies for EV-to-EBITDA. This places GKB Ophthalmics in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.67. GKB Ophthalmics' value of 3.70 is 74.8% below this benchmark. While the company's 10-year median is 12.06 vs. the industry median of 14.67, GKB Ophthalmics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GKB Ophthalmics's current EV-to-EBITDA of 3.70 is 74.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on GKB Ophthalmics. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GKB Ophthalmics's current EV-to-EBITDA is 3.70, which is 69% below median its own 10-year median of 12.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GKB Ophthalmics stock overvalued right now?
Based on GuruFocus' analysis, GKB Ophthalmics (NSE:GKB) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹126.23, compared to a current price of ₹63.00 — trading 50.1% below its estimated fair value. The current EV-to-EBITDA is 3.70, which is 69% below median its 10-year median of 12.06 and 74.8% below the Medical Devices & Instruments industry median of 14.67. GKB Ophthalmics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For GKB Ophthalmics (NSE:GKB), the current EV-to-EBITDA is 3.70 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GKB Ophthalmics (NSE:GKB) Overvalued in 2026?
Based on GuruFocus' analysis, GKB Ophthalmics stock appears to be undervalued.
The current stock price of ₹63.00 is trading 50.1% below its estimated GF Value™ of ₹126.23.
GuruFocus considers GKB Ophthalmics to be Significantly Undervalued.
Key valuation signals for NSE:GKB:
EV-to-EBITDA: 3.70 (69% below median its 10-year median of 12.06)
GF Value™: ₹126.23 vs. price of ₹63.00 (50.1% below fair value)
Industry Position: 74.8% below the Medical Devices & Instruments median (#53 of 516)
No single metric tells the full story. See the NSE:GKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GKB Ophthalmics Ltd is an India-based company engaged in manufacturing and exporting ophthalmics lenses. It manufactures glass and plastic lenses both semi-finished and finished forms. The other products of the company include Organic lenses, Glass moulds, and Bifocal moulds. The company sells its products in India and also exports globally. Geographically, the majority of its revenue is generated from outside of India.
44GF Score
Get the complete analysis for NSE:GKB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GKB has been successfully added to your 
